drugset
drugset / Trial / NCT07282587

Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma

NCT07282587 ↗

Phase 2 Recruiting 90 enrolled Jazz Pharmaceuticals
RandomizedSequentialOpen-labelTreatment

Summary

This is a two-stage Phase 2 trial evaluating the efficacy and safety of ONC206 in participants with Pheochromocytoma and Paraganglioma (PCPG).

Timeline

Start
2026-01-02
Primary completion
2028-12-15
Completion
2028-12-15

Drugs

EvaluationDrugModalityDoseRoute
Subject ONC206 Small molecule 150 mg —

Indications

pheochromocytoma-paraganglioma